← Back to headlines
Merck Exceeds Quarterly Sales Forecasts Driven by Keytruda Growth
Merck (MRK) reported quarterly sales that surpassed forecasts, primarily attributed to the strong performance and growth of its blockbuster drug Keytruda.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Canada Imposes Retaliatory Tariffs on US Goods Amid Trade Dispute
9m ago
Households and Corporates Positioned for Higher Yields Amid Rising Interest Rate Expectations
38m ago
New European Standards for Drinking Water Contact Materials Effective 2026
41m ago
SEC Investigates Trading Practices at Situational Awareness Hedge Fund
45m ago